This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
PEG MGF (2 mg Vial)
PEG MGF is a pegylated variant of mechano-growth factor, a muscle-derived IGF-1 splice isoform that is upregulated after mechanical stress or injury[2]. The unique C-terminal E peptide of MGF activates muscle satellite cells and local protein synthesis, initiating tissue repair and growth in addition to IGF-1 receptor signaling[3].
Quick Reference
What is PEG MGF?
Research overview based on the cited scientific literature.
• Goal: Support muscle recovery and regeneration through MGF’s satellite cell activation and local growth factor signaling[7][8].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage helps preserve peptide integrity and stability[10].
• Lyophilized material: Keep tightly sealed, dry, and protected from moisture and strong light. For longer-term laboratory storage, Bachem recommends storing lyophilized peptides below −15 °C[10].
• Prepared solutions: Stability depends on peptide sequence, solvent, concentration, and handling conditions. Long-term storage of peptide solutions is generally not recommended; laboratory solutions may be aliquoted and stored frozen when appropriate[10].
• Handling: Allow cold-stored lyophilized material to reach ambient temperature before opening to reduce moisture uptake[10].
• Avoid unnecessary repeated freeze–thaw cycles by using suitable laboratory aliquoting practices when required[10].
How is PEG MGF studied?
MGF is a splice variant of IGF-1 that is expressed in muscle tissue following mechanical loading or damage[2]. Unlike systemic IGF-1, MGF acts locally to activate satellite cells and initiate muscle repair processes through its unique C-terminal E peptide domain. Pegylation of MGF extends its half-life, allowing for once-daily subcutaneous administration instead of the frequent local injections required for native MGF. Animal studies have shown that MGF analogues can enhance muscle regeneration, bone healing, and cartilage repair when administered over several weeks.
What does the research report about PEG MGF?
Observations from preclinical and cell-based research.
• Animal studies demonstrate enhanced muscle, bone, and cartilage regeneration with MGF analogues administered over multiple weeks[4][6].
• MGF promotes myogenic precursor cell proliferation and improves muscle repair in models of injury or depletion[6][7].
• No human clinical trials have been completed; safety and efficacy in humans remain unestablished.
• Generally well tolerated in preclinical models; mild injection-site reactions may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on PEG MGF?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.